From:	Okuzumi-Tatsuya(奥住 竜哉)
To:	bernhard.valldorf@emdserono.com
Subject:	[PepTalk] EMD Serono - Ajinomoto - Site-specific conjugation for ADC - Thank you
Date:	Saturday, February 9, 2019 4:13:06 AM
Attachments:	image001.png 2019-01-16 PepTalk 2019 AJINOMOTO_Lunchon Presentation.pdf image003.png

---

Dear Bernhard Valldorf,

It was great meeting you in PepTalk. Thank you very much for your interest in our ADC conjugation technology AJICAP™.
It would be great if you circulate the information to whom may have an interest on conjugation technology in your company.

Advantage of AJICAPtm is as follows:

1. Straightforward CMC
   - Direct modification of intact antibody
   - No genetic modification required
2. Enhancement of Therapeutic Window compared to stochastic ADCs
   - Site specific, controlled DAR 2
3. Wide drug-linker compatibility: reactive group compatibility includes thiol, alkyne, azide, etc
4. High yields, short conjugation reaction times, ease to manufacture

We have already developed 2nd generation AJICAP™ which has:

- More streamlined reaction sequence
- No red/ox reaction
- Less aggregation - below 1%.

We could introduce the detail of AJICAP™ via TC or email upon your request. Please feel free to ask questions if something is unclear. We are happy to answer.

Best regards,

TATSUYA OKUZUMI, Ph.D.
Associate General Manager - R&D planning Dept.
P: +81.70.4360.7840 | 1-15-1, Kyobashi, Chuo-ku, Tokyo 104-8315, JAPAN
AJINOMOTO CO., INC. | www.ajinomoto.com

Exhibit 1018
AJINOMOTO CO., INC.
IPR2025-00283

From: Bernhard Valldorf
To: Okuzumi-Tatsuya(奥住 竜哉)
Subject: AW: [PepTalk] EMD Serono - Ajinomoto - Site-specific conjugation for ADC - Thank you
Date: Monday, February 11, 2019 3:43:57 PM
Attachments: image001.png
image003.png

Hi Tatsuya Okuzumi,

thank you for sending along the presentation. I have forwarded it to my ADC conjugation colleagues.

Best,

Bernhard

Dr. Bernhard Valldorf

Principal Scientist Research Pharmaceutics
Healthcare R&D | CPD | Pharmaceutical Technologies

Merck

Merck KGaA | Frankfurter Str. 250 | Postcode: D039/002 | 64293 Darmstadt | Germany
Phone: +49 6151 72 45231 | E-mail: bernhard.valldorf@merckgroup.com | www.merckgroup.com

Mandatory information can be found at http://mandatories.merckgroup.com
Pflichtangaben finden Sie unter: http://www.merckgroup.com/mandatories

---

Von: Okuzumi-Tatsuya(奥住 竜哉) <tatsuya_okuzumi@ajinomoto.com>
Gesendet: Samstag, 9. Februar 2019 04:13
An: Bernhard Valldorf <bernhard.valldorf@emdserono.com>
Betreff: [PepTalk] EMD Serono - Ajinomoto - Site-specific conjugation for ADC - Thank you

Dear Bernhard Valldorf,

It was great meeting you in PepTalk. Thank you very much for your interest in our ADC conjugation technology AJICAP™.
It would be great if you circulate the information to whom may have an interest on conjugation technology in your company.

Advantage of AJICAPtm is as follows:

1. Straightforward CMC
   - Direct modification of intact antibody
   - No genetic modification required
2. Enhancement of Therapeutic Window compared to stochastic ADCs
   - Site specific, controlled DAR 2

3. Wide drug-linker compatibility: reactive group compatibility includes thiol, alkyne, azide, etc
4. High yields, short conjugation reaction times, ease to manufacture

We have already developed 2nd generation AJICAP™ which has:

- More streamlined reaction sequence
- No red/ox reaction
- Less aggregation - below 1%.

We could introduce the detail of AJICAP™ via TC or email upon your request. Please feel free to ask questions if something is unclear. We are happy to answer.

Best regards,

TATSUYA OKUZUMI, Ph.D.
Associate General Manager - R&D planning Dept.
P: +81.70.4360.7840 | 1-15-1, Kyobashi, Chuo-ku, Tokyo 104-8315, JAPAN
AJINOMOTO CO., INC. | www.ajinomoto.com

This message and any attachment are confidential and may be privileged or otherwise protected from disclosure. If you are not the intended recipient, you must not copy this message or attachment or disclose the contents to any other person. If you have received this transmission in error, please notify the sender immediately and delete the message and any attachment from your system. Merck KGaA, Darmstadt, Germany and any of its subsidiaries do not accept liability for any omissions or errors in this message which may arise as a result of E-Mail-transmission or for damages resulting from any unauthorized changes of the content of this message and any attachment thereto. Merck KGaA, Darmstadt, Germany and any of its subsidiaries do not guarantee that this message is free of viruses and does not accept liability for any damages caused by any virus transmitted therewith.

Click http://www.emdgroup.com/emd/imprint/mail_disclaimer.html to access the German, French, Spanish and Portuguese versions of this disclaimer.